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Summary
 
In this study it is shown that both membrane-bound and soluble forms of signaling lympho-
cytic activation molecule (SLAM) induce proliferation and Ig synthesis by activated human B
cells. Activated B cells express the membrane-bound form of SLAM (mSLAM), the soluble (s)
and the cytoplasmic (c) isoforms of SLAM, and the expression levels of mSLAM on B cells are
rapidly upregulated after activation in vitro. Importantly, recombinant sSLAM and L cells
transfected with mSLAM efficiently enhance B cell proliferation induced by anti-
 
m
 
 mAbs,
anti-CD40 mAbs or 
 
Staphylococcus aureus
 
 Cowan I (SAC) in the presence or absence of IL-2,
IL-4, IL-10, IL-12, or IL-15. sSLAM strongly enhances proliferation of both freshly isolated B
cells and B cells derived from long-term in vitro cultures, indicating that SLAM acts not only
during the initial phase of B cell activation but also during the expansion of preactivated B cells.
In addition, sSLAM enhances production of IgM, IgG, and IgA by B cells activated by anti-
CD40 mAbs. SLAM has recently been shown to be a high affinity self-ligand, and the present
data suggest that signaling through homophilic SLAM–SLAM binding during B–B and B–T
cell interactions enhances the expansion and differentiation of activated B cells.
 
B
 
cell activation is initiated after recognition of specific
antigen by cell surface Ig, which in naive, unprimed B
cells is of IgM or IgD isotype. Cytokines and membrane-
bound costimulatory molecules expressed by activated
CD4
 
1
 
 T cells are required for subsequent proliferation, Ig
isotype switching and differentiation of activated B cells.
Cytokines produced by Th2-type cells, such as IL-4, IL-5,
IL-13, are considered to be primarily involved in providing
help for B cells, whereas Th1-type cytokines, IL-2 and
IFN-
 
g
 
, mediate delayed-type hypersensitivity reactions and
activate macrophages (1–3). In addition to T cells, mono-
cytes can regulate B cell proliferation and differentiation
through release of cytokines, such as IL-6, IL-8, and IL-10
(4–6), and B cell proliferation and differentiation also ap-
pear to be regulated by autocrine mechanisms. IL-1, IL-6,
IL-10, TNF-
 
a
 
, and lymphotoxin have been shown to be
produced, among other cell types, by activated B cells and
they enhance proliferation and differentiation of these cells
(7–11).
The CD40 ligand (CD40L)
 
1
 
 on activated CD4
 
1
 
 T cells,
which interacts with CD40 on B cells (12), was shown to
be a potent membrane-bound costimulatory molecule for
proliferation and differentiation of both human and murine
B cells (13–17). The B cell antigen CD19, the ligand of
which remains to be characterized, has also been shown to
mediate maturation, proliferation and differentiation of B
cells (18). In addition, CD70, a member of the TNF family
expressed by activated B and T cells, and the membrane
form of TNF-
 
a
 
, expressed by activated and HIV-infected
T cells, are involved in productive T–B cell interactions
 
1
 
Abbreviations used in this paper:
 
 aa, amino acid; CD40L, CD40 ligand;
MC, mononuclear cells; HPRT, hypoxanthine phosphoribosyltransferase;
PB, peripheral blood; PI, propidium iodide; RA, rheumatoid arthritis;
SAC, 
 
Staphylococcus aureus
 
 Cowan I; SH2, Src homology 2; SLAM, signal-
ing lymphocytic activation molecule.
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(19–21). Although several surface molecules can mediate
T–B cell collaboration, the role of CD40L appears to be
crucial, as is clearly demonstrated in patients with hyper-
IgM syndrome, who are unable to produce IgG, IgA, or
IgE because of mutations in their genes encoding CD40L
(22–25). However, the patients have normal or elevated
levels of IgM and normal numbers of B cells in the circula-
tion indicating that a CD40L-independent pathway of B
cell proliferation and differentiation is operational in these
patients. Moreover, CD40L-deficient mice have normal Ab
responses against thymus-independent antigens (26, 27),
and some T cell clones from patients with mutated CD40L
genes induce Ig isotype switching even in the presence of
neutralizing anti–TNF-
 
a
 
 mAbs (28), supporting the con-
clusion that yet to be characterized costimulatory molecules
contribute to the expansion, Ig isotype switching and dif-
ferentiation of activated B cells.
Signaling lymphocytic activation molecule (SLAM) is a
70-kD glycoprotein expressed by CD45RO
 
1
 
 T cells, im-
mature thymocytes, and a proportion of B cells (29). SLAM
is a member of the immunoglobulin gene superfamily and
belongs to the CD2 family of cell surface molecules (29, 30).
SLAM has limited homology to CD48 (26%), CD58/LFA-3
(17%), and 2B4 (28%), a signaling molecule expressed on
murine NK and cytotoxic T cells (31). Activated human
T cells express, in addition to membrane-form of SLAM
(mSLAM), mRNA encoding a soluble, secreted form of
SLAM (sSLAM) lacking 30 amino acids (aa) encompassing
the entire 22-aa transmembrane region (29). In addition, a
cytoplasmic (c) form lacking the leader sequence and a
variant membrane (vm)SLAM with a truncated cytoplasmic
tail were identified (29). SLAM was recently shown to be a
high-affinity self-ligand with an affinity constant of 0.1 nM
(Cocks, B.G., G. Aversa, S. Balasubramanian, C.-C.J.
Chang, B. Bennett, D. Peterson, J.M. Carballido, J. Pun-
nonen, and J.E. de Vries, manuscript submitted for publica-
tion). SLAM-Ig fusion protein specifically bound to SLAM
transfectants and to surface-immobilized SLAM as shown
by surface plasmon resonance. Engagement of SLAM by
specific mAb or sSLAM-induced proliferation of activated
human T cells in a CD28-independent manner, suggesting
that the T cell responses observed in CD28-deficient mice
may be partially or completely mediated via SLAM (29). In
addition, SLAM engagement induced IFN-
 
g
 
 production
even in Th2-type T cell clones, suggesting a role for SLAM
in directing cytokine synthesis in T helper cells (29).
In the present study, the expression and function of
SLAM on B cells was investigated. We demonstrate that
mSLAM is rapidly induced on B cells after activation with
anti-
 
m
 
 or anti-CD40 mAbs or 
 
Staphylococcus aureus
 
 Cowan
I (SAC). A recombinant form of sSLAM and murine L cells
transfected with mSLAM induced B cell proliferation in
the absence of other stimuli, and they strongly enhanced B
cell proliferation induced by anti-
 
m
 
 or anti-CD40 mAbs or
SAC in the presence or absence of cytokines IL-2, IL-4,
IL-10, IL-12, IL-13, or IL-15. These results indicate that
SLAM is a novel B cell growth and differentiation promot-
ing molecule.
 
Materials and Methods
 
Reagents.
 
Purified human recombinant (r) IL-4 and IL-10
were provided by Schering Plough Research Institute (Kenil-
worth, NJ). Purified rIL-2, rIL-13, and rIL-15 were kindly pro-
vided by Drs. Gerard Zurawski (DNAX), Satish Menon (DNAX)
and Robert Kastelein (DNAX), respectively. rIL-12 was pur-
chased from R&D Systems, Inc. (Minneapolis, MN). Unconju-
gated mAbs specific for CD3, CD4, CD8, CD14, CD16, and
CD56, PE- and FITC-conjugated mAb specific for CD20, and
control antibodies with irrelevant specificities were obtained from
Becton-Dickinson (San Jose, CA). The purified anti-CD40 mAb
89 (IgG1) (32) was kindly provided by J. Banchereau (Schering-
Plough France, Dardilly, France). mAb A12 specific for SLAM
(IgG1) was generated and purified as described (29). Beads coated
with anti-
 
m
 
 mAbs were obtained from Irvine Scientific (Santa Ana,
CA), and 
 
Staphylococcus aureus
 
 Cowan I cells (Pansorbin Cells) were
purchased from Calbiochem Novabiochem (La Jolla, CA). FITC-
conjugated mAb anti-IgD was obtained from Nordic Immunol-
ogy (Tilburg, The Netherlands).
 
Generation of sSLAM.
 
Recombinant sSLAM was expressed in
insect cells using the baculovirus expression system as described (33).
In brief, 
 
Spodoptera frugiperda
 
 (Sf9) cells were transfected with cDNA
encoding the soluble secreted form of SLAM (pSECslam) (29),
which was subcloned into the vector pVL1393 (Invitrogen, San
Diego, CA) using PCR and primers 5
 
9
 
-GAC TCA GAC GAA
TTC ATG GAT CCC AAG GGG CTC-3
 
9
 
 and 5
 
9
 
-AGC TAG
ATC AGA TCT GCT CTC TGG AAG TGT CAC-3
 
9
 
 fol-
lowed by a Bg1I/EcoRI digestion. A Flag sequence was fused to
the carboxy terminus of the protein, and the expressed recombi-
nant sSLAM was purified from the supernatants using an M2 anti-
Flag mAb affinity matrix (Eastman Kodak Company, New Haven,
CT) and glycine elution according to the manufacturer’s instruc-
tions.
 
Preparation of sSLAM-coated Beads.
 
Polystyrene latex beads with
a mean diameter of 0.6 
 
m
 
m (Interfacial Dynamics Corporation,
Portland, OR) were first incubated with anti-Flag mAb M2 for
30 min at room temperature (0.3 
 
m
 
g/10
 
8
 
 beads), and then an ad-
ditional 30 min on ice. The beads were washed with PBS. Re-
combinant sSLAM with a Flag tail was added to the beads at 0.3
 
m
 
g/10
 
8
 
 beads, and the suspension was incubated at room temper-
ature for 30 min. These sSLAM-coated beads were then washed
three times with PBS supplemented with 2% FCS, and finally re-
suspended in PBS plus 2% FCS.
 
Cell Preparations.
 
Blood samples and spleens were obtained
from healthy volunteers or from patients undergoing splenectomy
due to trauma, respectively. PBMC were isolated by centrifuga-
tion over Histopaque-1077 (Sigma Chem. Co., St. Louis, MO).
B cells were purified either by depleting non–B cells from hu-
man splenic MC by magnetic beads or sorting CD20
 
1
 
 cells using
flow cytometry. In brief, to deplete non–B cells from splenic MC
the cells were first stained with mAbs specific for CD3, CD4,
CD8, CD14, CD16, and CD56 at 4
 
8
 
C for 30 min. Then, the
cells were washed twice and incubated with magnetic beads
coated with sheep anti–mouse IgG mAbs (Dynal A.S., Oslo) at
4
 
8
 
C for 30 min. Positive cells were removed using a magnetic
field. The remaining cells were washed, counted, and an aliquot
of the cells was stained with FITC- or PE-conjugated anti–CD20
mAb or control Ab to analyze the purity of the cells. Always
 
.
 
97% of these negatively selected B cells were CD20
 
1
 
 (data not
shown). To positively sort total B cells, splenic MC were first
stained with FITC-conjugated mAb specific for CD20, and to
sort naive CD20
 
1
 
, sIgD
 
1
 
 B cells the cells were stained with anti-
CD20-PE and anti–IgD-FITC mAbs. Thereafter, the cells were 
995
 
Punnonen et al.
washed twice and single or double positive cells were sorted using
a FACStar
 
Ò
 
 Plus or Vantage cell sorter (Becton Dickinson). The
purity of the sorted cells also was analyzed, and it was always
98.5–100% (data not shown).
Murine L cells were transfected with cDNA encoding mSLAM
by electroporation and positive cells were selected by three rounds of
cell sorting. These L cell transfectants and normal L cells used as
controls were cultured in RPMI 1640 supplemented with 10%
FCS. The cells were harvested using a cell scraper, and the cells
were washed twice. Then, the cells were irradiated 7,300 rads and
washed again twice before adding them to B cell cultures. The ra-
tio of L cells to B cells at the onset of the culture was 1:6.
 
Culture Conditions.
 
Purified B cells were cultured in round-
bottomed 96-well plates (Linbro, McLean, VA) in 0.2 ml Yssel’s
medium supplemented with 10% FCS and incubated at 37
 
8
 
C in a
humidified atmosphere containing 5% CO
 
2
 
. Cultures were per-
formed in triplicate when proliferation of B cells was studied and
in quadruplicate when Ig synthesis was studied. Total negatively
selected B cells purified by magnetic beads were cultured at 10
 
5
 
cells/well, whereas sorted CD20
 
1
 
 or CD20
 
1
 
, sIgD
 
1
 
 B cells were
cultured at 3 
 
3
 
 10
 
4
 
 cells/well. 
 
Phenotypic Analysis of Cultured Cells.
 
B cells were cultured as
described above and they were harvested and washed after culture
periods varying from 6 to 72 h. FITC- and PE-conjugated mAbs
were added to the cell pellet at saturating concentrations and the
cells were then incubated at 4
 
8
 
C for 30 min. B cells cultured in
the presence of SAC were preincubated with 5% mouse serum at
4
 
8
 
C for 30 min due to nonspecific staining otherwise observed on
these cells. FITC- and PE-conjugated mAbs with irrelevant speci-
ficities were used as negative controls. Propidium iodide (PI) (2 
 
m
 
g
per 5 
 
3
 
 10
 
5
 
 cells) was added to all samples to exclude dead cells.
A total of 10
 
4
 
 cells with light scatter characteristics of lymphocytes
of each sample were analyzed using FACScan
 
Ò
 
 flow cytometer
and CellQuest software (Becton Dickinson).
 
Isolation of RNA and Reverse-Transcriptase PCR.
 
Cultured cells
were harvested and washed in PBS. RNA was isolated using
RNAzol B (CNNA; Biotech, Friendswood, TX) according to man-
ufacturer’s instructions. The samples were stored at 
 
2
 
80
 
8
 
C until
used. Reverse transcription was performed using Superscript R/T
enzyme, and the Superscript system protocol I (GIBCO BRL,
Gaithersburg, MD). The resulting cDNA was diluted 10-fold in
water and stored at 
 
2
 
70
 
8
 
C until used. 1–5 ng of cDNA was am-
plified with 1 U of Taq polymerase (Perkin Elmer Cetus, Nor-
walk, CT) and using 40 cycles of PCR (initial denaturation at
94
 
8
 
C for 2 min, then 30 s at 94
 
8
 
C; annealing 30 s at 55
 
8
 
C; exten-
sion 1 min, 72
 
8
 
C). To detect various isoforms of SLAM, specific
primers were used as follows: 5
 
9
 
-ATC ACT GGA GAA CAG
TGT-3
 
9
 
 and 5
 
9
 
-CCC AGC ATA CAC TGC CC-3
 
9
 
, to amplify
mSLAM, cSLAM and vmSLAM; 5
 
9
 
-ATC ACT GGA GAA
CAG TGT-3
 
9
 
 and 5
 
9
 
-TTC GTT TTA CCT GAG GGG TCT
G-3
 
9
 
 to amplify sSLAM; 5
 
9
 
-ACT TTG GAC TGC CTG TGT
GAG-3
 
9
 
 and 5
 
9
 
-CAG CCC AGT ATC AAG GTG CA-3
 
9
 
, to
amplify cSLAM; and 5
 
9
 
-CAG CTG GAG TGA AAA GGC-3
 
9
 
and 5
 
9
 
-CCG CAC CGG TCT TGG CGG-3
 
9
 
, to amplify
vmSLAM.
Primers for detection of hypoxanthine phosphoribosyltrans-
ferase (HPRT) transcripts were 5
 
9
 
-GTA ATG ATC AGT CAA
CGG GGG AC-3
 
9
 
 and 5
 
9
 
-CCA GCA AGC TTG CAA CCT
TAA CCA-3
 
9
 
. Each PCR product was electophoresed through
1.2% agarose gel, and visualized as ultraviolet fluorescence after
staining with ethidium bromide.
 
Measurement of Ig Production.
 
Purified B cells were cultured in
Yssel’s medium supplemented with 10% FCS as described above
for 12 d. IgM, IgG, IgA, and IgE levels in culture supernatants
were determined by ELISA as described previously (34). The sen-
sitivities of these ELISAs were 0.5 ng/ml.
 
Results
 
Expression of mSLAM on PB and Splenic B Cells.
 
The ex-
pression of mSLAM on peripheral blood (PB) and splenic B
cells was studied by double immunofluorescence using mAbs
specific for CD20 and SLAM (29). The expression level of
SLAM was generally higher on PB B cells than on splenic
B cells (Fig. 1). The percentages of SLAM
 
1
 
 cells among PB
B cells ranged between 20 and 50%, whereas those among
splenic B cells were generally less than 20%. B cells were
rather homogenous in terms of their SLAM expression, and
staining with SLAM-specific mAb generally caused a shift
in the staining pattern rather than resulted in the detection
of two separate populations of positive and negative cells
(Fig. 1). Because of the low proportion of B cells in PB
Figure 1. Expression of mSLAM on PB and splenic B cells. PB (a–e) or splenic (f–j) B cells were stained with FITC-conjugated anti-CD20 mAbs and
PE-conjugated anti-SLAM mAb A12 (open histograms) or PE-conjugated mouse IgG1 Ab with irrelevant specificity (stippled histograms). CD201 cells were
gated and expression of mSLAM was studied by flow cytometry. All histograms represent stainings of cells derived from different donors. PB B cells in a–d
were first enriched for B cells by depleting T cells, NK cells and monocytes by magnetic beads. Dead cells were always excluded by gating out PI1 cells. 
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mononuclear cells (MC), in some experiments B cells were
first enriched by depleting T cells, NK cells and monocytes
by magnetic beads. The results using total splenic MC or
PBMC were comparable to those using B cell enriched cell
populations (Fig. 1 and data not shown), indicating that cell
purification method did not affect the results.
 
mSLAM Is Upregulated on B Cells after Activation, and Acti-
vated B Cells Express Soluble, Cytoplasmic and Membrane
Forms of SLAM.
 
We next studied the effect of activation
on SLAM expression on B cells. As shown in Fig. 2 
 
A
 
,
mSLAM expression was moderately upregulated on B cells
cultured in the presence of medium alone. The expression
level of mSLAM was not significantly modulated by IL-2,
IL-4, or IL-10 (100 U/ml each), when compared to B cells
cultured in the presence of medium alone for up to 72 h
(Fig. 2 
 
A
 
 and data not shown). In contrast, SAC, anti-m
mAbs and anti-CD40 mAbs induced high levels of mSLAM
expression on .85% of the B cells during a culture period
Figure 2. Effect of B cell activation on mSLAM expression, and expression of SLAM isoforms in activated B cells. (A) B cells negatively selected by
magnetic beads were cultured in the presence of medium only, IL-4 (100 U/ml), anti-CD40 mAbs (10 mg/ml), SAC (0.005%), or anti-m mAbs (10 mg/
ml) for 6, 20, 48, or 72 h as indicated. Thereafter, the cells were harvested, washed and stained with mAb CD20-FITC and PE-conjugated SLAM-spe-
cific mAb A12 or PE-conjugated mouse IgG1 Ab with irrelevant specificity. Open and stippled histograms represent stainings with mAb A12 and control
Ab, respectively. PI was always added to exclude dead cells. mSLAM expression on CD201 cells was analyzed using FACScanÒ flow cytometer and
CellQuest software. A representative of three experiments is shown. (B) B cells purified by cell sorting were cultured in the presence of anti-CD40 mAbs
and IL-4 for 24 h, whereas PBMC were cultured in the presence of PMA (1 ng/ml) and Ca21 ionophore A23187 (500 ng/ml) for 4 h. The cells were
harvested and washed, and expression of different isoforms of SLAM was analyzed by RT-PCR using primers specific for each isoform as described in ex-
perimental procedures (m, membrane; s, soluble; c, cytoplasmic; vm, variant membrane). HPRT mRNA was amplified as a positive control.997 Punnonen et al.
of 20 h and the high expression levels were sustained for up
to 3 d. The most rapid effect was observed in response to
anti-m mAbs, which induced high levels of mSLAM ex-
pression on B cells already during a culture period of 6 h,
whereas optimal enhancement of mSLAM expression by
SAC and anti-CD40 mAbs was observed after 20 h. These
data indicate that mSLAM is strongly upregulated on B cells
after activation, and suggest that mSLAM is rapidly induced
after recognition of antigen by surface Ig.
Activated human T cells were previously shown to ex-
press two alternatively spliced isoforms of mSLAM (29). In
addition, they expressed a cytoplasmic and a soluble, se-
creted form of SLAM (29). Sorted, highly purified B cells
activated by anti-CD40 mAbs and IL-4 transcribed the
same isoforms of SLAM that are detectable in PBMC acti-
vated with PMA and Ca21 ionophore (Fig. 2 B), including
the secreted soluble form of SLAM. These data indicate
that, in addition to T cells, B cells are capable of producing
sSLAM, and suggest that the expression of SLAM on B and
T cells are regulated by similar mechanisms.
sSLAM Induces Proliferation of Highly Purified B Cells.
Since SLAM is a high-affinity self-ligand, we investigated
the role of SLAM–SLAM interactions in the regulation of
B cell function. As shown in Fig. 3, recombinant sSLAM
directly induced B cell proliferation of freshly isolated B cells
in a dose-dependent manner. sSLAM-induced B cell pro-
liferation was in the same range as that induced by IL-2
(Fig. 3), which has been previously described to directly in-
duce proliferation and differentiation of freshly isolated hu-
man B cells (35). IL-4 had no effect on B cell proliferation
under similar culture conditions (Fig. 3). Optimal effects by
sSLAM were observed at high concentrations of z20 mg/ml,
but it has to be taken into account that gel filtration analysis
has indicated that .99% of sSLAM is in dimeric form (data
not shown), and that only monomers are available for
binding to mSLAM.
The function of SLAM on B cells was also studied by
adding anti-SLAM mAb A12 to B cell cultures stimulated
with SAC or anti-CD40 in the presence or absence of IL-2,
IL-4, or IL-10. This mAb was previously shown to induce
proliferation of preactivated human T cells and T cell clones
(29). Similar effects on T cells were observed irrespective
whether mAb A12 or its F(ab9)2 or Fab fragments were used,
suggesting that cross-linking does not play a major role in
the signaling of SLAM. mAb A12 or its F(ab9)2 or Fab
fragments at concentrations 0.01–100 mg/ml had no en-
hancing effects on spontaneous or anti-CD40 mAb and IL-4–
induced B cell proliferation in six separate experiments
(data not shown). In fact, anti-SLAM mAb slightly inhib-
ited B cell proliferation induced by SAC or anti-CD40
mAbs plus IL-4 (data not shown). In addition, no stimula-
tory effects by mAb A12 were observed on B cells that had
been preactivated with SAC or anti-CD40 mAbs and IL-4
or IL-10 for 3–5 d, further indicating that mAb A12 cannot
replace sSLAM in induction of B cell proliferation.
Effects of sSLAM on B Cell Proliferation in the Presence of
Polyclonal B Cell Activators. sSLAM also strongly enhanced
proliferation of B cells cultured in the presence of other B
cell growth promoting signals. sSLAM had additive or
slightly synergistic effect on B cell proliferation induced by
anti-CD40 mAbs and IL-4 (Fig. 4 A), and it also enhanced
proliferation of B cells cultured in the presence of anti-m
mAbs or SAC (Fig. 4 B). These effects were observed irre-
spective of whether the cells were negatively selected using
magnetic beads or positively sorted using cell sorting, sug-
gesting that contaminating cells did not play a role in sSLAM-
induced B cell proliferation (Fig. 4 B). Moreover, sSLAM
had strong B cell growth promoting effects when saturating
concentrations (100 U/ml) of IL-2, IL-4, IL-10, IL-12, or
IL-13 were added to cultures stimulated with anti-CD40
mAbs, suggesting that the signaling pathway of sSLAM is
independent of that of these cytokines (Fig. 4 C). Impor-
tantly, the level of sSLAM-induced proliferation of CD40-
stimulated B cells was in the same range as that induced by
IL-2, IL-4, IL-12, or IL-13 under the same conditions (Fig.
4 C). In addition, although IL-10 was more potent than
sSLAM in inducing B cell proliferation in the presence of
anti-CD40 mAbs, sSLAM still enhanced IL-10–induced
response in a synergistic fashion. The B cell growth-pro-
moting effect of sSLAM was specific, because a control
protein that binds the human obese gene product (36), pro-
duced and purified in a manner similar to sSLAM, failed to
induce B cell proliferation when tested at concentrations
up to 25 mg/ml (data not shown).
Previously, mSLAM was shown to have two naturally
occurring isoforms with different cytoplasmic tails (29).
Myelin P0 is another homophilically interacting member of
the Ig supergene family, and, interestingly, it was demon-
strated that the cytoplasmic region of the molecule is re-
Figure 3. Effects of sSLAM on proliferation of freshly isolated splenic B
cells. Purified B cells were cultured in the presence of increasing concen-
trations of recombinant sSLAM, IL-2 (100 U/ml) or IL-4 (100 U/ml),
and proliferation was measured by [3H]thymidine incorporation during
the last 16 h of a 4-d culture. Open symbols represents mean 6 SD of
triplicate cultures obtained in three separate experiments in the presence
of sSLAM at concentrations indicated. Closed circle and square represent
mean 6 SD cpm obtained in response to IL-2 or IL-4, respectively, in
triplicate cultures in the same three experiments as described for sSLAM.998 The Role of SLAM in B Cell Activation
quired for optimal homophilic interactions of the extracellular
portion (37). To study the role of the carboxy-terminal
portion of sSLAM, which corresponds to the cytoplasmic
tail of mSLAM, a truncated form of sSLAM lacking this re-
gion was generated. As shown in Fig. 4 C, the two forms
of sSLAM had virtually identical effects on B cell prolifera-
tion, indicating that the carboxy-terminal tail of sSLAM is
not required for the B cell proliferation inducing effect of
the molecule.
Kinetics of sSLAM-induced B Cell Proliferation. The time
point of optimal effect of sSLAM on B cell proliferation
was dependent on the costimulus used in the cultures.
When B cells were activated by IL-10 and anti-m mAbs,
which typically induce rapid B cell activation (38), sSLAM
induced its optimal effects already after a culture period of
2 d (Fig. 5 A). However, when B cells were activated by
IL-10 and anti-CD40 mAbs, optimal effects were generally
observed on day 4 and enhancing effects by sSLAM were
still detectable after a culture period of 8 d (Fig. 5 A). The
kinetics were primarily dependent on whether anti-m or
anti-CD40 mAbs were used to costimulate the cells, be-
cause the results were essentially the same irrespective of
whether IL-2, IL-4, or IL-10 were included in these cul-
tures (data not shown). IL-2 significantly enhanced sSLAM-
induced B cell proliferation (Fig. 5 A), whereas IL-4 had
no or minimal effects (data not shown), which is consistent
with the fact that IL-2, but not IL-4, induces proliferation
Figure 4. Effects of sSLAM on proliferation of B cells activated with
anti-m mAbs, SAC, anti-CD40 mAbs and cytokines. (A) Negatively se-
lected B cells were cultured in the presence or absence anti-CD40 mAbs
(10 mg/ml), IL-4 (100 U/ml) and/or sSLAM (20 mg/ml) as indicated,
and proliferation was measured by [3H]thymidine incorporation during
the last 16 h of a 4-d culture. Mean 6 SEM of triplicate cultures in nine
separate experiments are shown. (B) Negatively selected B cells were
stimulated with anti-m mAbs (10 mg/ml), or sorted B cells were stimu-
lated with SAC (0.005%) in the presence or absence of sSLAM (20 mg/
ml). Mean 6 SD of triplicate cultures in a representative of three experi-
ments are shown. (C) Negatively selected B cells were stimulated with
anti-CD40 mAb in the presence or absence of IL-2, IL-4, IL-10, IL-12,
or IL-13 (100 U/ml each) as indicated, and proliferation was measured by
[3H]thymidine incorporation during the last 16 h of a 4-d culture. Mean 6
SD of triplicate cultures in a representative of four experiments are shown.
sSLAM, recombinant form of naturally occurring sSLAM; truncated sSLAM,
truncated recombinant form of sSLAM comprising only the region corre-
sponding to the extracellular portion of mSLAM.
Figure 5. Kinetics of sSLAM-induced B cell proliferation, and effects
of sSLAM on B cells derived from a long-term culture. (A) B cells were
purified by negative selection, and subsequently cultured in the presence
of medium only, IL-2 (100 U/ml), anti-m mAbs (10 mg/ml) plus IL-10
(100 U/ml), or anti-CD40 mAbs (10 mg/ml) plus IL-10 (100 U/ml) as
indicated. Open symbols with dashed lines represent data obtained in the
absence of sSLAM and closed symbols with solid lines represent data ob-
tained in the presence of sSLAM (20 mg/ml). Each value represents mean
of triplicate cultures in a representative of two experiments. (B) B cells
were cultured in the presence of anti-CD40 mAbs and IL-4 for 5 wk.
Thereafter, the cells were harvested, washed, and recultured in the pres-
ence of medium only, IL-2, IL-4, IL-10, and/or anti-CD40 mAbs in the
presence or absence of sSLAM. Each value represents mean 6 SD of trip-
licate cultures. Proliferation was always measured by [3H]thymidine in-
corporation during the last 16 h of a 4-d culture.999 Punnonen et al.
of freshly isolated B cells (Fig. 3). sSLAM alone or in com-
bination with IL-2 induced its optimal effect after a culture
period of 6 d (Fig. 5 A).
Anti-CD40 mAbs and IL-4 have previously been shown
to support long-term growth and survival of human B cells
(32). To investigate the effects of sSLAM on B cells derived
from long-term cultures, B cells were cultured for 5 wk in
the presence of anti-CD40 mAbs and IL-4, whereafter the
cells were recultured in the presence or absence of sSLAM.
As shown in Fig. 5 B, sSLAM significantly enhanced prolif-
eration of these B cells. sSLAM was also effective when IL-2,
IL-4, IL-10, or anti-CD40 mAbs, or combinations of these
were added to the cultures. Like sSLAM, IL-10 signifi-
cantly enhanced proliferation of these B cells, but the effect
of IL-10 could be further enhanced by sSLAM (Fig. 5 B).
Anti-CD40 mAbs and IL-4 did not significantly affect B
cell proliferation, which is likely to be due to their presence
during the primary cultures. These results indicate that SLAM
enhances B cell proliferation both during the initial phase
of B cell activation as well as during expansion of preacti-
vated B cells.
L Cells Transfected with mSLAM- and sSLAM-coated Poly-
styrene Latex Beads Induce B Cell Proliferation. To study the
effects of mSLAM on B cell proliferation murine L cells were
transfected with cDNA encoding mSLAM. Importantly, the
transfectants expressed mSLAM at levels comparable to those
on activated T cells (29) and B cells (Fig. 2 A), whereas un-
transfected L cells were completely mSLAM negative (Fig.
6, A and B). Irradiated mSLAM1 L cells strongly enhanced
B cell proliferation induced by anti-CD40 mAbs in the
presence of IL-4, IL-10 (Fig. 6 C), IL-2, or IL-15 (data
not shown). Like sSLAM, mSLAM transfectants also en-
hanced proliferation of anti-CD40–activated B cells in the
absence of exogenous cytokines.
Because normal L cells slightly enhanced B cell responses
in some experiments, we examined whether the B cell
growth promoting effects of mSLAM transfectants were
due to B cell growth factors released by L cells activated
through SLAM–SLAM interactions. Supernatants from both
untransfected L cells and SLAM transfectants did have B cell
growth promoting activities, but the responses were always
,15% of those induced by SLAM transfectants, and no sig-
nificant difference between supernatants derived from nor-
mal and transfected L cells could be observed (data not
shown). In addition, supernatants from irradiated L cells, ir-
respective of whether they were transfected or not, had no
effect on B cell proliferation induced by anti-CD40 mAbs
and IL-4 (data not shown). To further investigate the ef-
fects of surface-bound SLAM, we also studied proliferation
of B cells cultured in the presence of polystyrene latex
beads coated with sSLAM using mAb specific for the Flag-
sequence that was attached to the carboxy-terminus of
sSLAM. Similar to mSLAM transfectants, sSLAM-coated
beads  enhanced B cell proliferation induced by anti-CD40
mAbs and IL-4 (Fig. 6 D), supporting the conclusion that
SLAM activates B cells not only in its soluble form, but also
in its surface-bound form. These data also further indicate
that SLAM–SLAM interactions between the L cells did not
Figure 6. Expression of mSLAM on normal and mSLAM transfected L
cells, and the effects of mSLAM transfectants and sSLAM cross-linked to
polystyrene latex beads on B cell proliferation. Normal L cells (A) and L
cells transfected with cDNA encoding mSLAM (B) were stained with
PE-conjugated SLAM-specific mAb A12 (stippled histograms) or a PE-con-
jugated, isotype-matched control Ab with irrelevant specificity (open histo-
grams), and the cells were analyzed by flow cytometry. (C) Negatively se-
lected B cells were cocultured in the presence or absence of irradiated
(7,300 rad) normal or SLAM transfected L cells (L-SLAM), anti-CD40
mAbs (10 mg/ml), IL-4 (100 U/ml), and/or IL-10 (100 U/ml) as indi-
cated. Data represent mean 6 SD of triplicate cultures in three separate
experiments. (D) Polystyrene latex beads coated with sSLAM by using
anti-Flag mAb M2 (SLAM-beads) were cocultured with purified B cells
under culture conditions indicated. Polystyrene latex beads coated with
only anti-Flag mAb (aFlag-beads) were used as controls. Proliferation was
measured by [3H]thymidine incorporation during the last 16 h of a 4-d
culture. Data represent mean 6 SD of triplicate cultures.
play a role in the capacity of SLAM transfectants to induce
B cell proliferation.
Effects of sSLAM on Ig Synthesis by B Cells. Finally, we
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cells cultured in the presence or absence of anti-CD40 mAbs.
sSLAM significantly enhanced spontaneous IgM, IgG and
IgA synthesis produced by highly purified total B cells, but
the effects of sSLAM were generally more potent when
anti-CD40 mAbs were added to these cultures (Fig. 7 A).
The concentrations required for optimal induction of Ig
synthesis were comparable to those required for induction
of optimal B cell proliferation (,20 mg/ml). No IgE syn-
thesis was observed in these cultures (data not shown).
These results indicate that SLAM–SLAM interactions en-
hance not only B cell proliferation, but also Ig synthesis by
B cells.
To investigate whether sSLAM induces Ig isotype switch-
ing, sorted sIgD1 naive B cells were cultured in the pres-
ence of sSLAM. As shown in Fig. 7 B, sSLAM induced in a
dose-dependent manner IgM synthesis by sIgD1 B cells
cultured in the presence of anti-CD40 mAbs. However, no
IgG, IgA, or IgE was produced by these cells, indicating
that sSLAM induces human B cell differentiation, but fails
to induce Ig isotype switching.
Discussion
In the present study it is demonstrated that sSLAM and
mSLAM transfectants promote growth and differentiation
of human B cells. These effects were partially or completely
mediated by homophilic SLAM–SLAM interactions, be-
cause mSLAM was induced or upregulated on virtually all
B cells after activation in vitro, and because SLAM was re-
cently shown to be a high-affinity self-ligand (Cocks, B.G.,
G. Aversa, S. Balasubramanian, C.-C.J. Chang, B. Bennett,
D. Peterson, J.M. Carballido, J. Punnonen, and J.E. de
Vreis, manuscript submitted for publication). Thus, SLAM
is an unusual molecule in that it acts both as a signaling
membrane receptor and as a soluble and membrane-bound
growth promoting molecule. Other members of the CD2
family of cell surface molecules have previously been shown
to mediate both B and T cell activation. Engagement of
CD2 by a pair of agonistic mAbs induces T cell prolifera-
tion in the absence of T cell receptor signaling (39,40), and
CD58, the natural ligand for CD2 (41), on antigen-pre-
senting cells reduces the concentration of antigen required
for T cell activation (42). CD21 human B progenitor cell
lines also proliferate in response to agonistic mAbs specific
for CD2 (43), which is expressed on a subset of CD201
cells in human fetal thymus and bone marrow (43, 44).
Furthermore, blocking of CD2 on the surface of T cells in-
hibits the capacity of these cells to mediate productive T-B
cell interactions (45), and mAbs specific for CD58 induce
IgE isotype switching and IgE synthesis in a CD40-inde-
pendent manner by purified B cells cultured in the pres-
ence of IL-4 (46). Recombinant sSLAM and murine L cells
transfected with cDNA encoding mSLAM induced prolif-
eration and IgM, IgG, and IgA production by unfraction-
ated B cells, but only IgM production by sorted sIgD1 B
cells was observed, indicating that SLAM acts as a B cell
growth and differentiation promoting molecule, but not as
an Ig isotype switch factor.
sSLAM had B cell growth promoting effects even in the
absence of other stimuli, but the most potent effects were
observed when B cells were cultured in the presence of
polyclonal B cell stimuli and cytokines. Importantly, the
levels of [3H]thymidine incorporation induced by sSLAM
were comparable to those induced by IL-2, IL-4, IL-12, or
IL-13 in B cell cultures costimulated by anti-CD40 mAbs.
In addition, although sSLAM was less potent than IL-10 in
inducing B cell proliferation, it also strongly enhanced IL-10–
induced proliferative responses. Both sSLAM and murine
L cells transfected with cDNA encoding mSLAM had
growth promoting effects irrespective whether IL-2, IL-4,
IL-10, IL-12, IL-13, IL-15, anti-m mAbs, anti-CD40 mAbs,
or SAC were added to the cultures, suggesting that the sig-
naling pathway of SLAM is independent of that of these
B cell activators. The exact mechanisms of SLAM signaling
Figure 7. Effects of sSLAM on Ig synthesis by purified B cells. (A) neg-
atively selected total B cells or (B) sorted sIgD1 B cells were cultured in
the presence or absence of anti-CD40 mAbs (10 mg/ml) and sSLAM at
concentrations indicated for 12 d. Ig levels in the culture supernatants
were measured by isotype-specific ELISA. The data represent mean 6
SEM of quadruplicate cultures in four experiments (A) or triplicate cul-
tures in two experiments (B).1001 Punnonen et al.
remain to be studied, but it seems that tyrosine kinases that
contain Src homology 2 (SH2) domains are involved, be-
cause the intracellular portion of mSLAM has four tyrosine
residues (29), three of which conform to the consensus
sequence phosphotyrosine-hydrophobic-X-hydrophobic, de-
termined for binding to SH2 domains (47). Because sIgM
and CD40 mediate activation signals at different stages of B
cell responses, SLAM appears to costimulate B cells not
only during the initial antigen-induced activation phase,
but also during T cell–dependent, antigen-independent ex-
pansion of preactivated B cells. This notion is supported by
our kinetics studies, which indicated that sSLAM enhances
B cell proliferation at all time points during culture periods
of 2–8 d. Moreover, sSLAM enhanced proliferation of B
cells, which had been maintained in culture with anti-
CD40 mAbs and IL-4 for 5 wk.
It is well established that recognition of a specific antigen
results in vigorous B cell proliferation giving rise to the dark
zones of germinal centers in the lymph nodes. Despite
these regions are relatively devoid of T cells, recognition of
antigen by a single B cell may give rise to 104 antigen-spe-
cific B cells in 3 d, suggesting that the expansion of B
cells in germinal centers predominantly occurs in a T cell–
independent manner (17). The fact that SLAM is rapidly
induced on B cells after activation, and that the high ex-
pression levels are sustained for several days in vitro suggest
that SLAM–SLAM interactions may play a major role in
mediating homotypic B cell contacts in germinal centers
resulting in expansion of antigen-specific B cells.
SLAM was previously shown to preferentially stimulate
production of Th1-type cytokines. Engagement of SLAM
by the specific mAb A12 during antigen-specific T cell ac-
tivation induced IFN-g production even in Th2-like T cell
clones (29), suggesting that SLAM is primarily involved in
delayed-type hypersensitivity responses. However, despite
that Th2-type cytokines are generally considered to be the
main factors involved in B cell activation and Ig synthesis,
Th1 cytokines IL-2 and IFN-g have also been shown to
have direct effects on B cell function. IL-2 directly enhances
proliferation and Ig synthesis of in vitro and in vivo preacti-
vated B cells (35, 48), and IFN-g has been shown to in-
duce Ig isotype switching in murine B cells (49). IL-2 also
significantly enhanced sSLAM-induced proliferation of freshly
isolated B cells, whereas IL-4 was ineffective. Organ spe-
cific and systemic autoimmune diseases, such as rheumatoid
arthritis and systemic lupus erythematosus, are character-
ized by both increased production of Th1-type cytokines,
including IL-2, and hyperactivity of B cells with elevated
production of autoantibodies (50–53). In addition, patients
with rheumatoid arthritis (RA) have elevated levels of
CD45RO1 T cells, which were shown to coexpress SLAM
in healthy individuals (29), suggesting that expression of
SLAM may be elevated in T cells from patients with RA.
Indeed, we have recently demonstrated that synovial fluid
CD41 T cells from patients with rheumatoid arthritis ex-
press significantly higher levels of SLAM than PB CD41 T
cells (Isomäki, P., G. Aversa, B.G. Cocks, R. Luukkainen,
P. Toivanen, J.E. de Vries, and J. P., manuscript submitted
for publication). These data, together with the observations
that SLAM interacts homophilically, suggest that SLAM
may contribute to the productive T–B cell interactions and
B cell hyperactivity observed in patients with autoimmune
diseases.
Although our results clearly indicate that both mSLAM
and sSLAM are capable of inducing B cell proliferation, the
relative contribution of these two forms of SLAM in the
regulation of B cell function remains to be determined.
The fact that the expression level of mSLAM on L cells
transfected with cDNA encoding mSLAM was comparable
to that on activated B or T cells strongly suggests that
mSLAM acts as a B cell costimulatory molecule under phy-
siological conditions in vivo. Whether SLAM is in solution
or expressed on cell surface does not appear to affect the
function of the molecule, because mSLAM transfectants
and sSLAM had essentially similar effects on B cell prolifer-
ation. In addition, the region that corresponds to the cyto-
plasmic portion of mSLAM was not required for the func-
tion of sSLAM, because the effects of a truncated sSLAM
lacking this region were virtually identical to those of the
naturally occurring sSLAM. However, the high concentra-
tions of sSLAM required for induction of B cell prolifera-
tion suggest that mSLAM may be the dominant active form
in physiological situations. On the other hand, because SLAM
is a self-ligand, sSLAM primarily exists in a dimeric form in
solution. Based on gel filtration analysis, the proportion of
monomeric sSLAM is ,1% of the total concentration of
sSLAM (data not shown), and, therefore, the concentra-
tions of monomeric sSLAM available for homophilic bind-
ing to mSLAM are far less than the total concentration of
sSLAM.
Like activated T cells (29), activated B cells expressed
sSLAM and the potential cytoplasmic form, which lacks the
leader sequence. The relative contributions of these, and the
two different alternatively spliced isoforms of mSLAM, in
the regulation of B cell function remain to be determined.
Nevertheless, sSLAM had potent growth promoting effects
on B cells also when cross-linked to polystyrene latex beads
using mAb specific for the Flag sequence attached to the
molecule. These data are in line with the notion that sSLAM
primarily acts in its monomeric form through binding to
mSLAM, because the Flag sequence was attached to the car-
boxy-terminal end of sSLAM, and, therefore, the region
corresponding to the extracellular portion of mSLAM was
available for homophilic binding. Accordingly, transfection
of mSLAM into murine pre-B cell line Baf/3 triggered ag-
gregation of these cells, indicating that mSLAM also medi-
ates cell adhesion (Cocks, B.G., G. Averso, S. Balasubra-
manian, C.-C.J. Chang, B. Bennett, D. Peterson, J.M.
Carballido, J. Punnonen, and J.E. de Vries, manuscript sub-
mitted for publication). Consequently, it may also be possi-
ble that sSLAM, through binding to mSLAM, functions
as an inhibitor of cell adhesion mediated by mSLAM–
mSLAM interactions. However, this does not seem to be
the case, because sSLAM did not block B cell proliferation
induced by SLAM transfectants (unpublished observation).
The SLAM-specific mAb 12 did not induce or enhance1002 The Role of SLAM in B Cell Activation
B cell proliferation or Ig synthesis, indicating that it does
not act as a surrogate SLAM ligand on B cells. These data
are partially different from the data obtained on T cells, be-
cause both the mAb A12 (29) and sSLAM (Cocks, B.G., G.
Averso, S. Balasubramanian, C.-C.J. Chang, B. Bennett,
D. Peterson, J.M. Carballido, J. Punnonen, and J.E. de Vries,
manuscript submitted for publication) induced proliferation
of preactivated human T cells. Therefore, the functions of
SLAM on activated B and T cells may not be completely
comparable. However, because the mAb A12 recognizes
both isoforms of mSLAM with different cytoplasmic tails, it
remains possible that differential expression of these iso-
forms on the surface of B and T cells results in distinct sig-
naling events after SLAM engagement. Moreover, there
may be differences in B and T cells in the molecules that
associate with the cytoplasmic tails of mSLAM isoforms. In
addition, we cannot rule out the possibility that SLAM may
also signal through molecule(s) other than SLAM on B cells,
which might explain the differential effects of the mAb A12
on B and T cells. Unfortunately, preincubation of SLAM1
cells in the presence of mAb A12 did not block the binding
of sSLAM to mSLAM (data not shown), indicating that this
mAb cannot be used in blocking experiments to address
this question.
Taken together, the present study indicates that activated
B cells, like T cells, express four alternatively spliced iso-
forms of SLAM, and that both the soluble and the mem-
brane-bound forms of SLAM induce proliferation and Ig
synthesis by highly purified B cells, suggesting an important
role for this molecule in the regulation of T–B cell interac-
tions. In addition, because B cells are in close contact to
each other in germinal centers, homophilic SLAM interac-
tions during homotypic B cell contacts are likely to con-
tribute to the rapid antigen-driven expansion of B cells in
vivo, and may play a role in hyperactivity of B cells in dis-
ease situations.
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